REDWOOD CITY, Calif.
July 18, 2013
/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 3.8 million shares of its common stock, offered at a price of
per share to the public. The gross proceeds to AcelRx from this offering are expected to be approximately
, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by AcelRx. All of the shares in the offering are to be sold by AcelRx. The offering is expected to close on or about
July 23, 2013
, subject to the satisfaction of customary closing conditions. AcelRx has granted the underwriters a 30-day option to purchase up to an aggregate of 570,000 additional shares of common stock offered in the public offering.
Jefferies LLC and
& Co. acted as joint book-running managers for the offering, and Guggenheim Securities acted as co-manager for the offering.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A preliminary prospectus supplement relating to the offering has been filed with the SEC and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at
. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, at 520 Madison Avenue,
New York, New York
, 10022, or by calling (877) 547-6340, or by emailing
, or from
& Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
55402 or by calling (800)747-3924, or by emailing
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.